×

Sign In

Search
Home

Acadia Pharmaceuticals’ schizophrenia drug fails in late-stage study

By Thomson Reuters Mar 11, 2024 | 3:24 PM

(Reuters) – Acadia Pharmaceuticals said on Monday its experimental drug to treat negative symptoms of schizophrenia failed to meet the main goal in a late-stage study.

(Reporting by Mariam Sunny in Bengaluru)

Greece's former spy boss tells judges service did not use illegal malware in 2019-22

Russia's Lavrov says US-South Korea nuclear guideline adds concern, media reports

Olympics-Skateboarding-First day of skateboarding competition postponed amid bad weather

Nigeria courts convict 125 Boko Haram Islamist insurgents in mass trial

Israel tells Gazans to temporarily vacate southern Khan Younis areas

FSB foils militant attacks in southern Russia, RIA reports

Privacy Policy
Terms Of Service

Midwest Communications, Inc.

Copyright © 2024. All Rights Reserved.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.